The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide

DOI Web Site PubMed 8 References

Bibliographic Information

Other Title
  • レナリドミドを含む維持療法中にt(9;22)(q34;q11.2)が出現したBJP-λ型多発性骨髄腫
  • 症例報告 レナリドミドを含む維持療法中にt(9;22)(q34;q11.2)が出現したBJP-λ型多発性骨髄腫
  • ショウレイ ホウコク レナリドミド オ フクム イジ リョウホウ チュウ ニ t(9;22)(q34;q11.2)ガ シュツゲン シタ BJP-lガタ タハツセイ コツズイシュ

Search this article

Abstract

A 61-year-old man, who was diagnosed with Bence-Jones protein (BJP)-λ type multiple myeloma, was treated with bortezomib. Although maintenance therapy including lenalidomide was continued, t(9;22)(q34;q11.2) was detected in the marrow cells by a cytogenetic study. The increased incidence of a secondary malignancy after treatment with lenalidomide for multiple myeloma has been highlighted in previous clinical trials; however, reports on the presence of t(9;22)(q34;q11.2) or the onset of chronic myelogenous leukemia have yet to be found. Although the cause of chronic myelogenous leukemia with the lenalidomide treatment is not yet clear, it is an interesting case.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 54 (4), 388-391, 2013

    The Japanese Society of Hematology

References(8)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top